1. Home
  2. KARD

as of 11-20-2026 3:59pm EST

$11.56
$0.96
-7.71%
Stocks Nasdaq

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Founded: 2023 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 1.5B IPO Year: 2026
Target Price: $41.00 AVG Volume (30 days): 441.3K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -5.22 EPS Growth: N/A
52 Week Low/High: $12.23 - $27.00 Next Earning Date: 11-12-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -2.40 Index:
Free Cash Flow: N/A FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K

Nov 12, 2026

0001193125-26-456885

EX-99.1

2 ck0002123613-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

PRESS RELEASE

Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates

Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts

Completed enrollment in Phase 2b ataciguat KATALYST-AV trial; Week 48

topline data expected in 2H 2027

Cash position of $591.4 million supports multiple data readouts across all programs through 2027 and initiation of Phase 3 clinical trials

SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., Nov 12, 2026 — Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a precision cardiovascular company, today reported financial results for the third quarter ended September 30, 2026, and provided recent business updates.

“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options,” said Tassos Gianakakos, co-founder, chief executive officer and board chair of Kardigan. “Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy. We expect to share topline data from the Phase 2b portion of the study in the second quarter of 2027, representing the first data readout from any placebo-controlled trial of people with dilated cardiomyopathy. From an efficacy standpoint, data across three echocardiography parameters will help us assess the ability of danicamtiv to improve left ventricular function, the hallmark of DCM, while also examining potential to improve left atrial and right ventricular function. Importantly, given the adaptive 2b/3 study design, these data will give us an opportunity to adjust, if necessary, the Phase 3 registrational portion of the study, currently enrolling across both cohorts, to increase our probability of success.

Alongside danicamtiv, we completed enrollment in the Phase 2b KATALYST-AV trial of ataciguat and shared important new evidence at the recent AHA Scientific Session, which increases our confidence in the ataciguat program. We also continue to advance tonlamarsen in the Phase 2 KARDINAL-ASH trial, continuing enrollment with most clinical trial sites activated. For all three of our programs, we have the funding to deliver important value-inflecting data in 2027.”

Third Quarter 2026 and Recent Business Highlights

Danicamtiv: myosin activator in development for genetic and familial dilated cardiomyopathy

• Danicamtiv is designed to restore myosin function and availability, directly targeting the underlying sarcomeric defects in genetic dilated cardiomyopathy (DCM). The Company is currently evaluating

danicamtiv in the Phase 2b/3 KINSHIP-DCM adaptive, randomized, placebo-controlled clinical trial in patients with genetic DCM.

• Enrollment is complete in Cohort 2 (patients with non-MYH7/TTN variants or a family history of DCM) of the Phase 2b portion of the KINSHIP-DCM clinical trial, and topline data is expected in the second quarter of 2027; the Phase 3 trial is now enrolling across both cohorts.

Ataciguat: soluble guanylate cyclase activator in development for aortic stenosis

• Ataciguat is an investigational soluble guanylate cyclase (sGC) activator that is designed to restore sGC function to reduce calcium deposition and improve cardiac function. The Company is currently evaluating ataciguat in the Phase 2b KATALYST-AV clinical trial in patients with moderate aortic stenosis.

• On November 6, the Company announced completion of enrollment in the Phase 2b KATALYST-AV clinical trial (n=156) and reported insights from a pre-planned analysis of the baseline data, as well as real-world analyses of approximately 45,000 people with mild-to-moderate aortic stenosis.

o The primary endpoint in KATALYST-AV of aortic valve calcium (AVC) will be assessed at Week 48 to allow the effect on valve calcium to be read alongside measurements of disease progression, including aortic valve area (AVA), LV mass index, stroke volume index and E/e′.

o Real-world data demonstrates that aortic stenosis is a progressive disease of the valve and the myocardium, two areas potentially targeted by the unique mechanism of ataciguat. The data shows that people with both mild and moderate aortic stenosis with cardiac damage are more likely to progress rapidly and have worsening outcomes, which will help inform patient selection for enrichment in the ataciguat Phase 3 registrational trial. This data also provides new insights into the addressable patient population for ataciguat, spanning both mild and moderate aortic stenosis. An update on the Phase 3 trial is expected in the first half of 2027.

• While calcium remains an important independent marker of disease risk, it is not a marker of disease progression. It is best interpreted alongside AVA and measures of card

2026
Q2

Q2 2026 Earnings

8-K

Aug 11, 2026

0001193125-26-343395

EX-99.1

2 ck0002123613-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

PRESS RELEASE

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist

Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027

Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials

SOUTH SAN FRANCISCO, CA, and PRINCETON, NJ, AUG 11, 2026 — Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.

“Our IPO has positioned Kardigan to advance a portfolio of late-stage cardiovascular programs to address diseases where patients urgently need better treatment options,” said Tassos Gianakakos, co-founder, chief executive officer, and chair of the board of Kardigan. “As we initiate our Phase 3 KINSHIP-DCM trial, dose patients in our Phase 2b KARDINAL-ASH trial, and continue enrollment in our Phase 2b KATALYST-AV trial, we are entering a pivotal period with multiple clinical milestones expected over the next 12 months that will shape the registrational path for each of our medicines.”

Second Quarter 2026 and Recent Business Highlights

Danicamtiv: myosin activator in development for genetic DCM

• Danicamtiv is designed to restore myosin function and availability, directly targeting the underlying sarcomeric defects in genetic dilated cardiomyopathy (DCM).

• Danicamtiv is currently being evaluated in the Company’s KINSHIP-DCM Phase 2b/3 adaptive, randomized, placebo-controlled clinical trial.

• Preclinical and clinical evidence linking danicamtiv treatment to improvements in right ventricular function to be presented at the upcoming European Society of Cardiology Congress (ESC 2026). [Session: Late-Breaking Basic and Translational Science; Sunday, Aug 30th at 8:15 AM CEST]

• In July, the Company completed enrollment of Cohort 1 (myosin heavy chain 7, or MYH7, and titin, or TTN, patients) of the Phase 2b KINSHIP-DCM clinical trial and enrollment of the Phase 3 portion is now underway. The Company expects to share Phase 2b topline data in the first half of 2027.

Ataciguat: soluble guanylate cyclase (sGC) activator in development for CAVS

• Ataciguat targets valvular interstitial cells to slow osteogenic and calcific remodeling, an underlying driver of disease progression in calcific aortic valve stenosis (CAVS), and has demonstrated direct myocardial effects in improving both systolic and diastolic function, a hallmark of progressive disease that results in valvular heart failure.

• Ataciguat is currently being evaluated in the Company’s KATALYST-AV Phase 2b clinical trial in CAVS patients with moderate disease. The Company expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027.

Tonlamarsen: antisense oligonucleotide in development for ASH

• Tonlamarsen targets hepatic angiotensinogen (AGT) for the management of blood pressure in acute severe hypertension (ASH) post-hospitalization.

• Extended follow-up data from an earlier KARDINAL clinical trial assessing the effect of Tonlamarsen in uncontrolled hypertension will be presented at the upcoming European Society of Cardiology Congress (ESC 2026). [Session: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition; Sunday, Aug 30th from 1:45 - 3:00 PM CEST]

• Tonlamarsen is currently being evaluated in the Company’s KARDINAL-ASH Phase 2 clinical trial. In the second quarter, the Company randomized the first patient in KARDINAL-ASH and expects to share Phase 2 topline data in the first half of 2027.

Additional Highlights

• In June, the Company announced the closing of its initial public offering with aggregate gross proceeds of $460 million (before deducting underwriting discounts, commissions, and other offering expenses). Current cash runway supports continued advancement of danicamtiv, ataciguat, and tonlamarsen through clinical data readouts and the initiation of Phase 3 clinical trials across all three programs.

Second Quarter Financial Results

• Cash Position: Cash, cash equivalents and investments were $660.7 million as of June 30, 2026, compared to $335.5 million as of December 31, 2025. The increase reflects net proceeds from the Company’s initial public offering in June 2026, offset by cash used in operations.

• R&D Expenses: Research and development expenses were $56.4 million for the quarter ended June 30, 2026, compared to $35.8 million for the comparable prior-year period. The increase was primari

Share on Social Networks: